Urooj Niazi 
The Drug Regulatory Authority of Pakistan (DRAP) issued urgent safety alerts in early May 2026. As a warning of the presence of several counterfeit and substandard medicines in the market. The latest warning has made headlines across the country, as some of the products identified are common household first aid kit items that are often used for pain relief, fever management and digestive problems.
DRAP Issues Fresh Warning Over Counterfeit Medicines in Pakistan
The move comes as Pakistan is ramping up efforts to strengthen its pharmaceutical monitoring systems, improve the safety of public health and tighten oversight of distribution networks for counterfeit medicines.
Health authorities are calling on pharmacies, clinics and consumers to check medicines stored at home immediately and to verify product names and batch numbers before use.
Three Common Medicines Flagged in Latest DRAP Alert
Three well-known medicines that may already be in many homes are among the most worrying products in the latest alerts.
The first product flagged was Taskeen Dard Tablets (Batch 091), which the DRAP said was a counterfeit painkiller. The product’s composition and manufacturing source could not be confirmed through official channels, so authorities warned consumers not to use the product under any circumstances.
The alert also highlighted another medicine, Pain-Nil Tablets (Batch 01). The product was also identified as counterfeit, and chemists and distributors were immediately alerted to stop sales and remove all remaining stock from shelves.
The third major product mentioned in the warning is Duphalac Syrup (Batch 251986), which has been flagged for authenticity and quality compliance concerns.
Health experts said fake medicines may contain wrong ingredients, harmful substances or wrong dosages, which could lead to serious health complications for the patients.
Additional Medicines Recalled Across Pakistan
Apart from the three major products, DRAP also cited a number of other medicines recalled or restricted during recent inspections and laboratory testing.
They were:
- Barpon Infusion (Ibuprofen – Lot 202)
- WAFIN Injectables
- Maverick introduces
- Shine AMLO 5mg
- Tyclan 400 mg
- 600mg Linco-HCL
Some medicines failed quality assurance tests, while others posed concerns about risks of contamination, manufacturing irregularities or improper storage conditions.
The recalls are a sign of DRAP’s continued work to increase standards of medicine safety across Pakistan’s healthcare system and pharmaceutical supply chain.
Why Counterfeit Medicines Remain a Serious Concern
Counterfeit medicines remain a serious health threat in several developing healthcare markets around the world, including South Asia. Experts say fake painkillers and poorly made medicines can lead to treatment failure, allergic reactions, organ damage or deterioration of medical conditions.
Painkillers are particularly sensitive because they are often used by patients on their own, without immediate medical supervision. Such medicines are often kept at home by many families for headache, body pain, fever and seasonal illnesses.
The risk is much greater when counterfeit products are found in household medicine cabinets, as symptoms might not manifest immediately after ingestion.
Important Steps Pakistani Families Should Take
Following the latest notification from DRAP, health authorities have strongly advised consumers to immediately check household medicines.
Please cross-check the names of medicines, packaging details, and batch numbers against the recall alerts. If you find any of the products listed, stop using them right away.
Experts recommend the following precautions:
- Do not use medicines in damaged packaging or without clear
- Purchase medicines only from a licensed pharmacy
- Don’t ever buy loose tablets that don’t have verified packaging
- Store medicines in a cool, dry place, away from heat and humidity
- Consult qualified doctors before changing medication regimens
If you find any suspicious medicines, you should either return them to the pharmacy or dispose of them safely according to local medical waste guidelines.
Pakistan’s Pharmaceutical Monitoring System Expands
The recent recalls are part of larger efforts by Pakistan to modernise pharmaceutical regulation and consumer safety protections.
In recent years, DRAP has strengthened its capacity for laboratory testing, digital verification systems, and inspection mechanisms to reinforce oversight of pharmaceutical manufacturing and distribution.
The authorities are still working with healthcare institutions, pharmacies and provincial regulators to strengthen medicine quality assurance across the country.
Medical Experts Urge Immediate Attention to Side Effects
Doctors have advised patients to seek immediate medical help if they experience any unusual symptoms after using any suspected medicines.
Possible warning signs might be:
- Severe allergic reactions
- Shortness of breath
- Sudden dizzy spells
- Continued vomiting
- Swelling or irritation of the skin
- Unusual weakness or tiredness
Where possible, healthcare providers should also be made aware of the specific medicine ingested, including packaging and batch details.
Doctors say treating fake or polluted medicines much earlier dramatically increases the chances of a successful cure.
Growing Public Awareness Supports Safer Healthcare
Pakistan’s healthcare industry continues to become more engaged in medicine safety, regulatory transparency and consumer awareness. The recent DRAP alert is a sign of increasing institutional sensitivity to save patients from potentially harmful pharmaceutical products.
